Subtotal $0.00
CJC-1295 is a synthetic peptide based on the first 29 amino acids of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary gland to release growth hormone. Several amino acids were swapped to make the peptide more resistant to breakdown.
The original CJC-1295 also includes a chemical linker known as DAC (Drug Affinity Complex). DAC allows the peptide to attach to albumin, a common blood protein, which greatly extends how long it stays in the body.
The name CJC-1295 is used loosely. Some products labeled this way are a different, shorter-acting peptide without the DAC linker, sometimes called “CJC-1295 without DAC” or “Modified GRF (1-29).” These are not the same molecule.
CJC-1295 was tested in early-phase clinical studies in healthy adults in the mid-2000s, but it was not developed into an approved medicine.
Current status: Not FDA-approved.
In practical terms, CJC-1295 has not gone through the FDA review that a drug must pass before it can be marketed for use in people. There is no FDA-approved product that contains it.
GHRH analogs, including CJC-1295, are also prohibited in competitive sport under the World Anti-Doping Code.
Because CJC-1295 is not an approved drug, the FDA has not reviewed the contents or quality of products sold under the name.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply CJC-1295, and we do not point readers to anyone who does.
For personal medical questions, including questions about CJC-1295, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide.
Shop Now
